Cost-effectiveness of the once-daily efavirenz/emtricitabine/tenofovir tablet compared with the once-daily elvitegravir/cobicistat/emtricitabine/tenofovir tablet as first-line antiretroviral therapy in HIV-infected adults in the US

BACKGROUND: February 2013 US treatment guidelines recommend the once-daily tablet of efavirenz/emtricitabine/tenofovir (Atripla®) as a preferred regimen and the once-daily tablet of elvitegravir/cobicistat/emtricitabine/tenofovir (Stribild™) as an alternative regimen for first-line treatment of huma...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Juday, Timothy, Correll, Todd, Anene, Ayanna, Broder, Michael S, Ortendahl, Jesse, Bentley, Tanya
Formato: Artigo
Idioma:Inglês
Publicado em: Dove Medical Press 2013
Assuntos:
Original Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3770712/
https://ncbi.nlm.nih.gov/pubmed/24039438
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/CEOR.S47486
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados